ATI RN
ATI Pharmacology Proctored Exam 2024
1. Which of the following is NOT an opioid or NSAID?
- A. Morphine
- B. Ibuprofen
- C. Hydromorphone
- D. Acetaminophen
Correct answer: D
Rationale: Acetaminophen is the correct answer as it is not classified as an opioid or NSAID. Acetaminophen is considered a non-opioid analgesic, which means it works by a different mechanism than opioids and NSAIDs to relieve pain and reduce fever. Morphine, hydromorphone, and ibuprofen, on the other hand, are classified as opioids or NSAIDs. Morphine and hydromorphone are opioids, while ibuprofen is an NSAID (Nonsteroidal Anti-Inflammatory Drug), all of which work through different mechanisms compared to acetaminophen.
2. A patient is prescribed warfarin therapy for an artificial heart valve. Which of the following laboratory values should the nurse monitor for a therapeutic effect of warfarin?
- A. Hemoglobin
- B. Prothrombin time (PT)
- C. Bleeding time
- D. Activated partial thromboplastin time (aPTT)
Correct answer: B
Rationale: The correct answer is to monitor Prothrombin time (PT) when a patient is on warfarin therapy. Warfarin affects blood clotting, and PT is used to assess the therapeutic effect of this medication. Hemoglobin (Choice A) is not directly affected by warfarin therapy and does not reflect its therapeutic effect. Bleeding time (Choice C) measures the time it takes for bleeding to stop after a standardized cut and is not specific to warfarin therapy. Activated partial thromboplastin time (aPTT) (Choice D) is more commonly used to monitor heparin therapy, not warfarin.
3. Which of the following drugs is associated with the reaction of tendon dysfunction?
- A. Digitalis
- B. Niacin
- C. Tetracycline
- D. Fluoroquinolones
Correct answer: D
Rationale: Fluoroquinolones are known to be associated with tendon dysfunction or rupture. These drugs can weaken the tendons, leading to potential issues such as tendonitis or even tendon rupture. It is essential for healthcare providers to be cautious when prescribing fluoroquinolones, especially in patients who may be at higher risk for tendon-related complications.
4. A healthcare provider is reviewing the health history of a client who is starting therapy with tamoxifen. The healthcare provider should recognize that tamoxifen is contraindicated in which of the following clients?
- A. A client with a history of deep-vein thrombosis
- B. A client with a history of migraine headaches
- C. A client with a history of hypertension
- D. A client with a history of anemia
Correct answer: A
Rationale: Tamoxifen is contraindicated in clients with a history of thromboembolic events, such as deep-vein thrombosis, due to the increased risk of blood clots. The estrogenic effects of tamoxifen can further increase the risk of thromboembolic events, making it unsafe for individuals with a history of deep-vein thrombosis. Choice B (migraine headaches), Choice C (hypertension), and Choice D (anemia) are not contraindications for tamoxifen therapy. Migraine headaches, hypertension, and anemia do not pose the same risk of adverse effects related to blood clot formation as deep-vein thrombosis does.
5. A healthcare professional is preparing to administer a dose of Hydromorphone IV to a client. Which of the following actions should the healthcare professional take?
- A. Administer the medication over 5 minutes.
- B. Administer a dose of Naloxone prior to giving the Hydromorphone.
- C. Assess the client's blood pressure prior to administration.
- D. Inject the medication into the client's subcutaneous tissue.
Correct answer: A
Rationale: The correct action for the healthcare professional preparing to administer IV Hydromorphone to a client is to administer the medication over 5 minutes. This slow administration is crucial to reduce the risk of hypotension and respiratory depression. Administering the medication rapidly can lead to adverse effects. Option B, administering Naloxone prior to Hydromorphone, is incorrect because Naloxone is used as an antidote for opioid overdose, not as a routine pre-medication. Option C, assessing the client's blood pressure before administration, is important but not the immediate action to take to reduce adverse effects of Hydromorphone. Option D, injecting the medication into the client's subcutaneous tissue, is incorrect as Hydromorphone is meant for intravenous administration for rapid onset of action.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access